Bethany Sensenig - 18 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 16:43:00 UTC
Previous filing
02 Oct 2025
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sensenig Bethany Director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 20 Feb 2026 0001899935

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Unit Award $0 +2,989 $0.000000 2,989 18 Feb 2026 Common Stock 2,989 Direct F1, F2
transaction SUPN Director Stock Option (Right to Buy) Award $0 +4,977 $0.000000 4,977 18 Feb 2026 Common Stock 4,977 $50.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2 These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
F3 Each option vests on February 18, 2027.